FDA's denial of the two remaining sunscreen time-and-extent applications, including one for an ingredient available OTC through a new drug application process, signals “nothing's going to get to market” anytime soon through monograph changes, says an advisor for an advocacy group.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?